title: HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients.
abstract: OBJECTIVE
  A number of studies demonstrate that the polymorphisms in the 5 region of HTR2C play a pivotal role in antipsychotic drug efficacy. Since risperidone is an antagonist of HTR2C, polymorphic variations in HTR2C may explain variability in response to risperidone treatment. We analyzed HTR2C polymorphisms for association with efficacy of risperidone monotherapy.
  
  
  METHODS
  We genotyped five SNPs distributed throughout the HTR2C gene and examined them for association using the Brief Psychiatric Rating Scale score in 130 Chinese schizophrenic patients following an 8-week period of risperidone monotherapy. All the patients were receiving the atypical antipsychotic drug treatment for the first time and had a 4-week medication-free period before research began.
  
  
  RESULTS
  We found rs518147, rs1023574 and rs9698290 were significantly associated with risperidone treatment in female patients (F = 4.75, degrees of freedom = 2 and p = 0.011; F = 4.329, degrees of freedom = 2 and p = 0.016; F = 4.188, degrees of freedom = 2 and p = 0.019, respectively) and they were also found to be in one linkage disequilibrium block.
  
  
  CONCLUSIONS
  Our results indicate that variants in the HTR2C promoter region are likely to affect the risperidone therapeutic effect in female mainland patients. It may be helpful to investigate a combination of other clinical factors to predict atypical antipsychotic efficacy.
authors.affiliation: Bio-X Center, Key Laboratory for the Genetics of Developmental & Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, PR China.
authors.forename: Bao-Cheng
authors.initials: BC
authors.lastname: Liu
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Xing-Wang
authors.initials: XW
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhi-Yun
authors.initials: ZY
authors.lastname: Wei
authors.forename: Jue
authors.initials: J
authors.lastname: Ji
authors.forename: Feng-Ping
authors.initials: FP
authors.lastname: Yang
authors.forename: Chun-Ling
authors.initials: CL
authors.lastname: Wan
authors.forename: Yi-Feng
authors.initials: YF
authors.lastname: Xu
authors.forename: Guo-Yin
authors.initials: GY
authors.lastname: Feng
authors.forename: Lin
authors.initials: L
authors.lastname: He
authors.forename: Guang
authors.initials: G
authors.lastname: He
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D010054:Brief Psychiatric Rating Scale; D005260:Female; D017353:Gene Deletion; D005838:Genotype; D006801:Humans; D015810:Linkage Disequilibrium; D008875:Middle Aged; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D012045:Regulatory Sequences, Nucleic Acid; D018967:Risperidone / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone